VIEWPOINT

Will serum enzymes and other proteins find a clinical application in the early diagnosis of myocardial infarction?

Adam D Timmis

Until recently there was little interest in the early diagnosis of myocardial infarction because the duration of symptoms had little impact on the hospital management strategy. Attitudes changed after the publication of the major mortality studies of thrombolytic therapy which showed not only that treatment improves prognosis but also that the earlier it is given after the onset of symptoms the greater is the benefit.14 This stimulated a review of the three diagnostic methods used clinically for the diagnosis of acute myocardial infarction (electrocardiogram, enzyme analysis, non-invasive imaging) to determine which could provide the earliest diagnosis.2

There is no doubt that in terms of cost, practicality, and accuracy the presenting electrocardiogram remains the best method for early diagnosis. Regional ST elevation occurs within seconds of the onset of coronary occlusion7 and its diagnostic specificity for acute infarction is close to 100%.69 Nevertheless, its sensitivity may be as low as 60%, reflecting the significant minority of patients who present with non-diagnostic changes such as left bundle branch block, ST depression, or T wave inversion: occasionally, the presenting electrocardiogram is entirely normal.89 In the past, serum enzyme analysis has proved useful for retrospective confirmation of infarction in these patients, but the timing of enzyme release and until recently the logistics of the method effectively ruled it out as a means of early diagnosis. Now, however, kits are available for the rapid analysis of creatine kinase and its MB isoenzyme and a myoglobin assay can be diagnostic within 4 h of the onset of symptoms.10-12 If these serum markers of myocardial infarction provide early diagnosis when the electrocardiogram is non-diagnostic will they save lives by allowing increased application of thrombolytic therapy and other interventions aimed at reducing mortality?12 Though serum markers of myocardial infarction may permit early diagnosis in cases where the electrocardiogram is unhelpful, this is unlikely to improve outcome. Indeed, there is real concern that it may have the opposite effect by leading to the use of thrombolytic agents in a group of patients in which the risk of treatment exceeds the potential benefit.

If serum markers of myocardial infarction are to be useful in early diagnosis it will be in patients who present with chest pain and left bundle branch block. In those in whom infarction is confirmed mortality is high and there is much to gain from successful thrombolysis.13 However, it is questionable whether this role will be realised because most cardiologists would not wish to wait for laboratory data before starting treatment of these high risk patients. Patients with chest pain and other non-diagnostic electrocardiogram patterns have a much better prognosis and do not require such early diagnosis and treatment. Thus Yusuf et al found that only 1.2% of patients entered into the ISIS-1 (International Study of Infarct Survival) trial developed cardiac arrest or died when the presenting electrocardiogram was non-diagnostic compared with 11% when it showed ST elevation.6 Of course, these were selected, low risk patients not all of whom had a definite infarct. Nevertheless, the database of > 1000 consecutive patients with acute infarction treated at Newham General Hospital confirms that patients without ST elevation have a hospital mortality of < 5%, which is about one third that seen in patients with ST elevation. Clearly, therefore, hospital outcome in these patients with non-diagnostic electrocardiograms is good compared with patients with ST elevation, and this must diminish the potential value of thrombolytic therapy and other interventions designed to improve survival. Indeed, subgroup analysis of the ISIS-2 trial, indicated that mortality reduction in response to treatment was greatest in subgroups at greatest risk of death (for example, women, older patients, patients with previous infarction or anterior infarction), and no apparent benefit for either streptokinase or aspirin could be demonstrated in patients with normal electrocardiograms or ST depression.2 In this latter respect, the finding accorded with the GISSI subgroup analysis.1 Only the LATE study has suggested a small benefit in outcome for patients without ST elevation randomised to thrombolytic therapy, but it is not clear to what extent patients with left bundle branch block confounded the mortality statistic.14 The balance of evidence from subgroup analyses of the randomised trials of thrombolytic therapy, therefore, tends to strengthen the hypothesis that patients with non-diagnostic electrocardiograms may not show the same benefit from thrombolytic therapy as patients with ST elevation. If true, this calls into question the need for early diagnosis by rapid analysis of enzymes or other proteins.
released from necrosing cardiac myocytes.

Why do some patients with myocardial infarction present without ST elevation, why do these same patients have such a good prognosis, and why do they obtain little apparent benefit from thrombolytic therapy? A unifying hypothesis that may account for all these observations is provided by DeWood et al's finding of a 35% coronary patency rate in patients with "transmural" infarction after the first 12–24 h; in non-Q wave infarction the patency rate is as high as 74%.16 Even in the early hours after infarction, patency rates of 29% have been reported and in these patients ST elevation resolves very rapidly, the enzyme rise is reduced, and indices of left ventricular damage (ejection fraction, QRS, Q wave development) are lower than in patients with coronary occlusions.17 ST changes also resolve rapidly after successful thrombolyis18-19 and the assumption must be that, in many patients with non-diagnostic electrocardiograms, there is spontaneous thrombolysis by endogenous mechanisms before presentation to hospital. This causes ST elevation to resolve and aborts the process of infarction. This limits infarct size and reduces hospital mortality. Of course, cardiac enzymes and other markers of myocardial injury are often raised on presentation (reflecting recent, not necessarily continuing, infarction) but if the coronary artery is already patent no additional benefit can be expected from thrombolytic therapy, which merely exposes the patient to the risk of haemorrhagic side effects. Treatment directed at preserving coronary patency with aspirin and heparin is the logical alternative. This presumably accounts for the value of these drugs in unstable angina,20 another chest pain syndrome caused by subocclusive coronary disease,21 which (as recently confirmed at the 1993 meeting of the European Society of Cardiology by the TIMI (Thrombolysis in Myocardial Infarction) investigators (TIMI 3B Trial) is not helped by thrombolytic therapy.

At present the use of laboratory tests to make an early diagnosis of myocardial infarction in the patient who presents with chest pain and a non-diagnostic electrocardiogram is not clinically justified. This policy would be expensive because even if sensitivity and specificity were 100% only about half the patients tested would have a positive result.9 In fact a recent study shows that the sensitivity of the tests early after the onset of symptoms is lower than that of the ECG, ranging from 34% for creatine kinase to 57% for myoglobin. So those patients who might benefit most from receiving early thrombolytic therapy would be those least likely to be identified.22 Most importantly, however, it must be recognised that in the absence of left bundle branch block patients with non-diagnostic electrocardiograms have a good prognosis and there is no clear evidence that it can be improved by thrombolytic therapy. Serial electrocardiograms are a cheaper and more practical alternative for diagnostic purposes: if ST elevation, left bundle branch block, or signs of true posterior infarction develop it will indicate coronary occlusion and the need for thrombolysis. Inevitably, this conservative policy will mean that occasionally patients with electrocardiographically-silent coronary occlusions will not receive the thrombolytic therapy that would have benefited them. How much harm is caused by the consequences of inappropriate thrombolytic therapy in patients who do not benefit—about five in every thousand—who experience a major bleed or fatal haemorrhagic stroke as a direct result of the treatment.2

6 Griffin B, Timmis AD, Crick JC, Sowton E. The evolution of myocardial ischaemia during percutaneous trans-luminal coronary angioplasty. Eur Heart J 1987;8:
14 LATE Trial Study Group. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-69.
Will serum enzymes and other proteins find a clinical application in the early diagnosis of myocardial infarction?

A. D. Timmis

Br Heart J 1994 71: 309-310
doi: 10.1136/hrt.71.4.309

Updated information and services can be found at:
http://heart.bmj.com/content/71/4/309.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/